Skip to main content
. 2011 Aug 19;6(4):279–283. doi: 10.1159/000330946

Table 4.

Clinical response to later-line taxane-based therapy

Later-line therapy CR, n (%) PR, n (%) SD, n (%) PD, n (%) Response unknown, n (%)
Docetaxel (n = 13) 0 (0.0) 2 (15.4) 1 (7.7) 2 (15.4) 8 (61.5)
Paclitaxel (n = 26) 1 (3.8) 8 (30.8) 8 (30.8) 2 (7.7) 7 (26.9)
All (n = 39) 1 (2.6) 10 (25.6) 9 (23.1) 4 (10.3) 15 (38.5)

CR = Complete response, PR = partial response, SD = stable disease; PD = progressive disease.